Our data combined with these studies suggests that ascorbate may support TET1/2 function in gliomas and lead to increased 5-hmC, but intervention phase 0 trials are first required to assess whether glioma ascorbate content can be manipulated. The gene discussed is TET1; the disease is central nervous system cancer.